These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35885007)

  • 1. Systematic Review on Saliva Biomarkers in Patients Diagnosed with Morbus Alzheimer and Morbus Parkinson.
    Wolgin M; Zobernig M; Dvornyk V; Braun RJ; Kielbassa AM
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of salivary biomarkers in Parkinson's disease.
    De Bartolo MI; Belvisi D; Mancinelli R; Costanzo M; Caturano C; Leodori G; Berardelli A; Fabbrini G; Vivacqua G
    Neural Regen Res; 2024 Dec; 19(12):2613-2625. PubMed ID: 38595280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review.
    Bougea A; Koros C; Stefanis L
    J Neural Transm (Vienna); 2019 Nov; 126(11):1373-1382. PubMed ID: 31401695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.
    Calderón-Garcidueñas L; Avila-Ramírez J; Calderón-Garcidueñas A; González-Heredia T; Acuña-Ayala H; Chao CK; Thompson C; Ruiz-Ramos R; Cortés-González V; Martínez-Martínez L; García-Pérez MA; Reis J; Mukherjee PS; Torres-Jardón R; Lachmann I
    J Alzheimers Dis; 2016 Sep; 54(2):597-613. PubMed ID: 27567860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
    Sengupta U; Kayed R
    Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In search of Parkinson's disease biomarkers - is the answer in our mouths? A systematic review of the literature on salivary biomarkers of Parkinson's disease.
    Figura M; Friedman A
    Neurol Neurochir Pol; 2020; 54(1):14-20. PubMed ID: 32003440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation.
    Shim KH; Kang MJ; Suh JW; Pyun JM; Ryoo N; Park YH; Youn YC; Jang JW; Jeong JH; Park KW; Choi SH; Suk K; Lee HW; Ko PW; Lee CN; Lim TS; An SSA; Kim S;
    Alzheimers Res Ther; 2020 Jul; 12(1):83. PubMed ID: 32660565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction.
    Compta Y; Revesz T
    J Parkinsons Dis; 2021; 11(1):107-121. PubMed ID: 33325398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary alpha-synuclein as a potential fluid biomarker in Parkinson's disease: A systematic review and meta-analysis.
    Kharel S; Ojha R; Bist A; Joshi SP; Rauniyar R; Yadav JK
    Aging Med (Milton); 2022 Mar; 5(1):53-62. PubMed ID: 35309157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease.
    Pawlik P; Błochowiak K
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33671562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.